GRAIL (GRAL) in Pivotal Point Check: 34% Jump in One Day - FDA Review Without Flaws Signals Start for Multi-Cancer Revolution!

FDA Report as Price Driver: On September 21, the FDA published a positive review of the multi-cancer early detection test Galleri. Positive Advisory Recommendation: On September 24, an independent FDA expert panel voted majority in favor of the test's approval. Solid Financial Cushion Despite Losses: Despite a quarterly loss of around 110 million USD with 44.7 million USD in revenue, liquid assets exceeding 860 million USD secure continued development until the planned market launch in 2027. GRAIL is focused on cancer early detection...